EUDAMED’s first four modules become mandatory on 28 May 2026 - what this means for medical device manufacturers
The European Commission (EC) has formally declared that the first four modules of EUDAMED - the European Database on Medical Devices - will become mandatory as of 28 May 2026.
MedNet EC-REP
Author

Which modules are affected
Starting on 28 May 2026, the following modules will require compulsory use under Regulation (EU) 2024/1860:
- Actor registration (registration of economic operators - manufacturers, authorised representatives, importers, etc.)
- UDI/Devices registration (device registration and unique device identifier requirements)
- Notified Bodies & Certificates (registration of notified bodies and associated device certificates)
- Market Surveillance (module supporting oversight of devices on the market)
Timing and transition
The EC published the notice declaring functionality of these modules on 27 November 2025, triggering the mandated six-month transition period under the Regulation - hence the effective date of 28 May 2026.
Until that date, use of the modules remains voluntary, but after 28 May 2026 their use becomes a legal requirement for any responsible economic operator under MDR/IVDR.
Conclusions & Recommendations
- The mandatory activation of the first four EUDAMED modules from 28 May 2026 signals a major shift toward increased transparency and regulatory compliance across the EU medical device market.
- All manufacturers, authorised representatives, importers, and notified bodies should review their readiness - including internal processes and data - to ensure timely registration.
- With our expertise, MedNet EC-REP GmbH can help navigate the transition smoothly. Contact your Regulatory Affairs Manager for further information.
Source: European Commission
Related Articles

MDCG 2025-10: New PMS Guidance for MDR & IVDR
The MDCG released new PMS guidance in December 2025. Learn what MDCG 2025-10 means for your MDR and IVDR compliance strategy.

MHRA Introduces New Device Registration Fee: What Manufacturers Need to Know
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has updated its “DORS Fees Guidance 2.1”, introducing a new annual fee model for device registration.

Regulatory Affairs Bulletin: Intended Purpose vs Intended Use under MDR & IVDR
European regulations EU 2017/745 (MDR) and EU 2017/746 (IVDR) require precise definitions in technical documentation, and the distinction (or overlap) between intended purpose and intended use remains a topic of operational significance. This bulletin clarifies the regulatory definitions, their implications, and guidance interpretations.
Stay Updated
Get the latest regulatory updates and industry insights delivered to your inbox.
Subscribe to Updates